cliffordfosterr kormidelník
Registrace: 28.1. 2023 Příspěvky: 262
|
Zaslal: čt 16. květen, 2024 9:16 Předmět: What is the pharmacokinetic profile of Vriligy 60 Mg? |
|
|
Vriligy 60 mg is a medication primarily used to treat premature ejaculation in men. It contains the active ingredient dapoxetine, which is a selective serotonin reuptake inhibitor (SSRI) specifically developed for this purpose.
As for its pharmacokinetic profile:
Absorption: Dapoxetine is rapidly absorbed after oral administration, reaching peak plasma concentrations (Cmax) within 1 to 2 hours after ingestion. Food does not significantly affect the absorption of dapoxetine.
Distribution: Vriligy 60mg has a relatively small volume of distribution, indicating that it stays primarily within the blood plasma rather than distributing extensively into tissues. Protein binding of dapoxetine is moderate (around 99%), primarily to albumin.
Metabolism: Dapoxetine undergoes extensive metabolism primarily by the liver enzyme CYP2D6, with minor contributions from CYP3A4 and CYP1A2. The main metabolites formed are desmethyldapoxetine and dapoxetine-N-oxide.
Elimination: Dapoxetine and its metabolites are mainly excreted via the urine, with approximately 61% of the administered dose recovered in the urine within 48 hours. The half-life of dapoxetine is relatively short, approximately 1-1.3 hours, indicating rapid elimination from the body.
Special populations: Pharmacokinetics of dapoxetine may be altered in certain populations, such as the elderly, individuals with renal impairment, or those with hepatic impairment. |
|